A phase 2 trial of capecitabine for recurrent and/or metastatic salivary duct carcinoma – CAESAR trial

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516956-16-01

Acronym

116162

Enrollment

Registered

2025-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Salivary Duct Carcinoma

Brief summary

Best Overall Respone Rate

Detailed description

Progression-free survival, Overall survival, Clinical benefit rate, Disease control rate, Safety, Quality of life

Interventions

DRUGCAPECITABINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Best Overall Respone Rate	—

Secondary

Measure	Time frame
Progression-free survival, Overall survival, Clinical benefit rate, Disease control rate, Safety, Quality of life	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026